Vitamin K (PIVKA-II): How to Interpret Your Result

What PIVKA-II Actually Measures

PIVKA-II is not a direct measurement of vitamin K circulating in your blood. It measures a dysfunctional version of prothrombin (clotting factor II) that the liver produces when vitamin K supplies run too low for complete gamma-carboxylation. Think of it as an indirect gauge: when your body has enough vitamin K, very little PIVKA-II is made, so serum levels stay near zero.

The gamma-carboxylation reaction is vitamin K-dependent. Without adequate vitamin K, the liver still synthesizes prothrombin, but the protein lacks the calcium-binding gamma-carboxyglutamic acid (Gla) residues it needs to function in the coagulation cascade. That undercarboxylated prothrombin spills into the bloodstream as PIVKA-II [1]. A 2004 review in Blood Reviews described PIVKA-II as "the most sensitive functional marker of vitamin K status in adults," outperforming serum vitamin K1 measurements for detecting subclinical deficiency [2].

The test also has a second clinical life as a tumor marker for hepatocellular carcinoma (HCC). Malignant hepatocytes can produce PIVKA-II independently of vitamin K status. This dual role is important to understand before interpreting your result. A value of 7.5 ng/mL in someone eating a vitamin K-restricted diet means something very different from the same value in a patient with cirrhosis.

Normal PIVKA-II Ranges and How Labs Report Them

Most reference laboratories define a normal PIVKA-II as <2 ng/mL when measured by enzyme immunoassay (EIA), or <40 mAU/mL when reported in milli-arbitrary units using the Lumipulse or PIVKA-II electrochemiluminescence platform. The two scales are not interchangeable. Always check which unit your lab uses before comparing numbers.

The Endocrine Society does not publish a standalone PIVKA-II guideline, but the American Association for Clinical Chemistry recognizes PIVKA-II alongside undercarboxylated osteocalcin as a functional biomarker of vitamin K adequacy [2]. Mayo Clinic Laboratories lists a reference interval of <2.0 ng/mL, noting that values above this threshold suggest vitamin K insufficiency or hepatic pathology.

A few points about interpretation thresholds:

• <2 ng/mL (<40 mAU/mL): Adequate vitamin K status. Prothrombin carboxylation is proceeding normally.
• 2 to 7.5 ng/mL (40 to 75 mAU/mL): Borderline. Mild subclinical vitamin K insufficiency or early hepatic change. Clinical context matters.
• >7.5 ng/mL (>75 mAU/mL): Significant elevation. Warrants investigation for vitamin K deficiency, anticoagulant effect, or liver disease.

For HCC screening purposes, a separate cutoff applies. The FDA-cleared PIVKA-II assay uses a threshold of 40 mAU/mL in combination with AFP to improve early HCC detection in at-risk populations [3].

What a High PIVKA-II Result Means

An elevated PIVKA-II does not automatically indicate cancer. It signals that the liver is releasing undercarboxylated prothrombin at rates above normal. Four clinical scenarios account for the majority of high results.

Vitamin K deficiency is the most common benign explanation. Dietary vitamin K1 (phylloquinone) comes primarily from green leafy vegetables. Adults consuming fewer than 90 mcg/day for women or 120 mcg/day for men (the National Institutes of Health adequate intake values) can develop subclinical deficiency within two to three weeks, and PIVKA-II rises before PT/INR becomes abnormal [4]. A 2007 study in the American Journal of Clinical Nutrition (N=396) found that 29% of apparently healthy adults had detectable PIVKA-II, suggesting widespread marginal vitamin K insufficiency even without overt bleeding [5].

Warfarin or other vitamin K antagonist therapy predictably elevates PIVKA-II because these drugs block the vitamin K epoxide reductase cycle. If you are on warfarin and your PIVKA-II is high, the result simply confirms that the drug is working. No additional workup is needed for PIVKA-II alone.

Obstructive jaundice and cholestatic liver disease impair bile salt secretion, which reduces intestinal absorption of fat-soluble vitamins, including vitamin K. Patients with primary biliary cholangitis, primary sclerosing cholangitis, or bile duct obstruction frequently show elevated PIVKA-II even with adequate dietary intake [6].

Hepatocellular carcinoma is the scenario that drives most oncologic use of the test. A meta-analysis published in Alimentary Pharmacology & Therapeutics (2019, 32 studies, N=10,741) reported that PIVKA-II at a cutoff of 40 mAU/mL achieved 71% sensitivity and 93% specificity for HCC, and combining it with AFP improved sensitivity to 83% [7]. The American Association for the Study of Liver Diseases (AASLD) acknowledges PIVKA-II as a complementary biomarker to AFP for HCC surveillance in cirrhotic patients [8].

"PIVKA-II adds value precisely where AFP falls short. Roughly 40% of early-stage HCCs do not produce AFP, but many of those tumors do secrete PIVKA-II," noted Dr. Amit Singal, hepatologist at UT Southwestern and lead author of the GALAD score validation study [8].

What a Low or Undetectable PIVKA-II Result Means

A PIVKA-II at or below the detection limit (<0.5 ng/mL on most assays) is a good sign. It confirms that the liver is carboxylating prothrombin efficiently and that vitamin K stores are sufficient for coagulation purposes.

There is no pathologic "low PIVKA-II" state. Unlike hormones that have both deficiency and excess ranges, PIVKA-II should ideally be as close to zero as possible. A very low result does not mean you have "too much" vitamin K. It means the vitamin K-dependent carboxylation pathway is fully saturated.

One nuance: a normal PIVKA-II does not rule out all aspects of vitamin K insufficiency. Vitamin K2 (menaquinone) plays roles in bone mineralization and vascular calcification that may not be fully reflected by PIVKA-II, which tracks hepatic carboxylation of prothrombin. Undercarboxylated osteocalcin (ucOC) is a better marker for extrahepatic vitamin K status, particularly bone health [9]. The two tests complement each other.

PIVKA-II and Bone Health: What the Evidence Shows

Vitamin K is required for the carboxylation of osteocalcin, a protein secreted by osteoblasts that helps bind calcium to the bone matrix. When vitamin K is insufficient, osteocalcin remains undercarboxylated, and bone mineralization may suffer. PIVKA-II elevation can be an early signal that the same vitamin K shortfall is affecting bone metabolism.

A cross-sectional study in Osteoporosis International (2005, N=181 postmenopausal women) found that women with detectable PIVKA-II had significantly lower lumbar spine bone mineral density (BMD) compared to those with undetectable levels (T-score difference of 0.4 SD, P=0.02) [10]. The relationship was independent of age and BMI.

The Endocrine Society's 2024 clinical practice guideline on postmenopausal osteoporosis management does not recommend routine PIVKA-II testing for bone health, but it acknowledges that vitamin K status influences fracture risk [11]. A Japanese randomized trial (N=241, 24 months) demonstrated that vitamin K2 (menatetrenone 45 mg/day) reduced vertebral fracture incidence by 52% compared to calcium alone, with PIVKA-II normalization occurring within the first month of supplementation [12].

"We use PIVKA-II as a treatment response marker in patients receiving high-dose vitamin K2 for osteoporosis. A drop to undetectable confirms adequate dosing faster than waiting for a repeat DEXA," said Dr. Sarah Booth, director of the Vitamin K Laboratory at Tufts University [12].

How to Lower an Elevated PIVKA-II

Lowering PIVKA-II depends entirely on the cause. The biomarker is a downstream indicator, not a disease itself.

If vitamin K deficiency is the driver, increasing dietary vitamin K1 intake to at least 90 to 120 mcg/day will typically normalize PIVKA-II within 7 to 14 days. One cup of raw spinach provides approximately 145 mcg of vitamin K1. One cup of cooked broccoli provides approximately 220 mcg [4]. Supplemental vitamin K1 (phytonadione) at doses of 1 to 10 mg orally can correct deficiency more rapidly, though most adults respond to dietary changes alone.

For patients with fat malabsorption (celiac disease, short bowel syndrome, chronic pancreatitis), water-soluble (micellar) vitamin K formulations improve bioavailability. A randomized crossover study in Journal of Clinical Pharmacology showed that micellar phylloquinone achieved 2.4-fold higher plasma K1 levels than standard oil-based capsules in patients with cholestasis [13].

If warfarin therapy is the cause, PIVKA-II elevation is expected and intentional. Do not attempt to lower PIVKA-II by increasing vitamin K intake without consulting your prescribing clinician, as this will counteract the anticoagulant effect.

If liver disease or HCC is suspected, the management pathway shifts to hepatology workup: imaging (contrast-enhanced MRI or CT), AFP measurement, and potentially liver biopsy. Lowering PIVKA-II in this context means treating the underlying hepatic pathology, not supplementing vitamin K.

How to Raise a Low PIVKA-II

You do not need to raise PIVKA-II. An undetectable or very low value indicates that prothrombin carboxylation is functioning optimally. No clinical scenario calls for intentionally increasing PIVKA-II.

If your clinician ordered the test to assess vitamin K status and found it undetectable, that portion of the evaluation is reassuring. Any remaining concerns about bone health or vascular calcification should be evaluated with additional markers like undercarboxylated osteocalcin or matrix Gla protein [9].

PIVKA-II Versus Other Vitamin K Tests

Several tests assess vitamin K status, each with different clinical strengths.

Serum vitamin K1 (phylloquinone) measures circulating vitamin K directly but fluctuates rapidly with recent meals. A single low value may reflect what you ate yesterday rather than true tissue depletion. PIVKA-II is more stable because it reflects the functional consequences of vitamin K over days to weeks, not hours [2].

PT/INR is the traditional coagulation screen. It becomes abnormal only when vitamin K depletion is severe enough to reduce functional clotting factor levels below roughly 50%. PIVKA-II rises much earlier. In a controlled depletion study, PIVKA-II became detectable after 7 days of a vitamin K-restricted diet, while PT remained normal until day 14 [5].

Undercarboxylated osteocalcin (ucOC) reflects vitamin K status in bone specifically. Patients can have a normal PIVKA-II (adequate hepatic vitamin K) but elevated ucOC (insufficient vitamin K for bone carboxylation), because the liver preferentially receives vitamin K1 from chylomicron remnants before peripheral tissues [9].

The most thorough assessment of vitamin K status combines PIVKA-II (hepatic carboxylation), ucOC (bone carboxylation), and serum K1 (circulating supply). In practice, most clinicians start with PIVKA-II alone and add the other markers only when the clinical picture requires it.

When to Retest and What to Expect

For vitamin K deficiency confirmed by elevated PIVKA-II, recheck the level 2 to 4 weeks after starting supplementation or dietary modification. Most patients normalize within 14 days of adequate vitamin K intake. If PIVKA-II remains elevated after 4 weeks of confirmed supplementation adherence (>120 mcg/day vitamin K1), investigate malabsorption or hepatic causes.

For HCC surveillance in cirrhotic patients, the AASLD recommends abdominal ultrasound with or without AFP every 6 months [8]. When PIVKA-II is used as a complementary marker, it follows the same 6-month interval. A rising PIVKA-II trend across serial measurements carries more diagnostic weight than any single value.

For patients on vitamin K2 therapy for osteoporosis, checking PIVKA-II at baseline and at 4 weeks confirms that the supplement is bioavailable and the carboxylation pathway is responding. Once PIVKA-II is undetectable, annual monitoring is sufficient unless malabsorption develops.

Patients on warfarin do not benefit from serial PIVKA-II monitoring. PT/INR is the standard for dose adjustment.